Open Access
| Issue |
BIO Web Conf.
Volume 240, 2026
The 2026 International Conference on Biomedicine, Neuroscience and Biostatistics (ICBNB 2026)
|
|
|---|---|---|
| Article Number | 01002 | |
| Number of page(s) | 5 | |
| Section | Biomedicine, Neuroscience and Biostatistics | |
| DOI | https://doi.org/10.1051/bioconf/202624001002 | |
| Published online | 24 June 2026 | |
- Y. Gu, Q. Zhao, Clinical Progresses and Challenges of Bispecific Antibodies for the Treatment of Solid Tumors. Molecular Diagnosis & Therapy 28(6): 669–702 (2024). [Google Scholar]
- A. C. McCue, et al., Engineering a tumor-selective prodrug T-cell engager bispecific antibody for safer immunotherapy. mAbs 16(1) (2024). [Google Scholar]
- F. Cattaruzza, et al., Precision-activated T-cell engagers targeting HER2 or EGFR and CD3 mitigate on-target, off-tumor toxicity for immunotherapy in solid tumors. Nature Cancer 4(4): 485–501 (2023). [Google Scholar]
- Q. Wang, et al., Recent advances in matrix metalloproteinases-responsive nanoprobes for cancer diagnosis and therapy. Reviews in Analytical Chemistry 41(1): 198–216 (2022). [Google Scholar]
- J. Habermann, et al., A Competition‐Based Strategy for the Isolation of an Anti‐Idiotypic Blocking Module and Fine‐Tuning for Conditional Activation of a Therapeutic Antibody. Biotechnology Journal 19(12) (2024). [Google Scholar]
- J. Wang, et al., Stimuli‐responsive linkers and their application in molecular imaging. Exploration 4(4) (2024). [Google Scholar]
- B. Todaro, et al., Targeting Peptides: The New Generation of Targeted Drug Delivery Systems. Pharmaceutics 15(6) (2023). [Google Scholar]
- K. M. J. Aertker, et al., Exploring molecular determinants and pharmacokinetic properties of IgG1-scFv bispecific antibodies. mAbs 16(1) (2024). [Google Scholar]
- G. You, et al., Bispecific Antibodies: A Smart Arsenal for Cancer Immunotherapies. Vaccines 9(7) (2021). [Google Scholar]
- A. Naing, et al., CX-072 (pacmilimab), a Probody ® PD-L1 inhibitor, in advanced or recurrent solid tumors (PROCLAIM-CX-072): an open-label dose-finding and first-in-human study. Journal for ImmunoTherapy of Cancer 9(7) (2021). [Google Scholar]
Current usage metrics show cumulative count of Article Views (full-text article views including HTML views, PDF and ePub downloads, according to the available data) and Abstracts Views on Vision4Press platform.
Data correspond to usage on the plateform after 2015. The current usage metrics is available 48-96 hours after online publication and is updated daily on week days.
Initial download of the metrics may take a while.